Comparative Pharmacology
Head-to-head clinical analysis: SITAGLIPTIN versus TRADJENTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SITAGLIPTIN versus TRADJENTA.
SITAGLIPTIN vs TRADJENTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases active incretin (GLP-1 and GIP) levels by preventing their degradation, thereby enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner.
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It slows the inactivation of incretin hormones GLP-1 and GIP, increasing their levels, which stimulates insulin secretion and suppresses glucagon release in a glucose-dependent manner.
100 mg orally once daily.
5 mg orally once daily.
None Documented
None Documented
12.4 hours; supports once-daily dosing with effect ≥24 h due to sustained DPP-4 inhibition.
Clinical Note
moderateSitagliptin + Gatifloxacin
"Sitagliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSitagliptin + Rosoxacin
"Sitagliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSitagliptin + Levofloxacin
"Sitagliptin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateSitagliptin + Trovafloxacin
"Sitagliptin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is approximately 12.5 hours at steady state, consistent with once-daily dosing and supporting 24-hour DPP-4 inhibition.
Renal: ~87% unchanged in urine (active tubular secretion); fecal: <13% (metabolites).
Approximately 85% of the dose is excreted in feces (mostly as unchanged parent drug) and about 5% in urine (largely as metabolites). Biliary excretion accounts for the majority of fecal elimination.
Category A/B
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor